Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5171425 | 1.00 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL5169273 | 1.00 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL5643216 | 0.91 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL5644989 | 0.91 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL16893898 | 0.91 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL16893868 | 0.91 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL16893869 | 0.91 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL16893895 | 0.91 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL5646382 | 0.91 | PTGS2 (0.66) | PTGS2PTGS1 | |
| SCHEMBL20921399 | 0.90 | PTGS2 (0.77) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778662-A1 | PHOTORACEMIZATION OF 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006011045-A1 | PHOTORACEMIZATION OF 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006011052-A1 | METHOD FOR THE RACEMIZATION OF 2-TRIFLUORO-2H-CHROMENE-3-CARBOXYLIC ACIDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060020023-A1 | Racemization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| US-20060016683-A1 | Photoracamization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020023-A1 | Racemization method | STS, SQLE, HAO2 | PTGS2 1102/4885PTGS1 1630/4885 |
| US-20060016683-A1 | Photoracamization method | CYP3A43, CRY2, CRY1 | PTGS2 728/4885PTGS1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.